



Date: 09/11/2020

To,
The Board of Directors,
Ishita Drugs & Industries Limited,
Ahmedabad.

LIMITED REVIEW REPORT

We have reviewed the accompanying of unaudited financial results of **ISHITA DRUGS AND INDUSTRIES LIMITED** for the period **01 July 2020 to 30 Sep 2020** (The Statement) being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim financial information performed by the Independent auditor of the entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with Indian accounting standards prescribe under section 133 of companies Act, 2013 read with relevant rules issued there under and another recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of
JAYMIN SHAH & ASSOCIATES



CA Mayank Sancheti
M No. 170863
Date: 09/11/2020
Place: Ahmedabad
UDIN: 20170863AAAADU1251

Corp. Office : 410-411, Lilamani Corporate Heights, Opp. Ramapir Brts Bus Stand, Nr. Ozone Aangan, New Wadaj, Ahmedabad - 380013, Gujarat
Branch Office : 504, Palladium Business Hub, Above Pantaloons, Opp. 4D Mall - PVR Cinema, Visat-Gandhinagar Highway, Ahmedabad-382424

☐ CA Mayank Sancheti +91 8000331632 / 7048685472
Deepak Surana +91 9429913706
● GSTIN : 24AAOFJ1119R1ZY

✉ camayanksancheti@gmail.com
dpaksurana4u@gmail.com

ISHITA DRUGS AND INDUSTRIES LIMITED

CIN: L24231GJ1992PLCO17054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand

Ahmedabad - 382170

Website: www.ishitadrugs.com

Contact: +91 7226995613/14/15

Unaudited Financial Results for the Quarter and Half year Ended September 30, 2020

Particulars	Amount in Lacs except Per Share data					
	Quarter Ended			Half Year Ended		Year Ended
	3 Months Ended Un-audited 30-Sep-20	3 Months Ended Un-audited 30-Jun-20	3 Months Ended Un-audited 30-Sep-19	6 Months Ended Un-audited 30-Sep-20	6 Months Ended Un-audited 30-Sep-19	12 Months Ended Audited 31-Mar-20
1 INCOME						
Revenue from Operations	379,629	230,401	360,766	610,030	746,830	1481,812
Other Income	3,683	0,380	2,419	4,063	5,317	17,646
	383,312	230,781	363,185	614,093	752,147	1499,458
2 EXPENSES						
(a) Cost of Material Consumed	303,691	153,916	277,961	457,607	575,695	1135,527
(b) Purchase of Stock-in-Trade	0,000	1,469	0,000	1,469	2,903	9,253
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-9,285	-2,597	2,058	-11,882	7,955	-0,265
(d) Employee Benefit Expense	25,902	25,611	26,528	51,513	53,263	109,795
(e) Finance Cost	0,618	0,567	1,084	1,185	1,969	3,470
(f) Depreciation, Depletion and Amortisation Expense	4,436	4,437	3,580	8,873	7,795	17,747
(g) Other Expense	38,814	35,316	35,483	74,130	70,159	152,587
	388,114	258,447	340,087	678,880	738,814	1525,887
	Total Other Expenses	35,316	35,483	74,130	70,159	152,587
	Total Expenses	218,719	346,694	582,895	719,739	1428,114
3	Total Profit before Exceptional Items and Tax	19,137	16,491	31,198	32,408	71,344
4	Exceptional Items	0,000	0,000	0,000	0,000	0,000
5	Total Profit before Tax	19,137	16,491	31,198	32,408	71,344
6	Tax Expense	4,000	3,000	3,794	7,000	7,510
7	Current Tax	0,000	0,000	0,000	0,000	0,000
8	Deferred Tax	4,000	3,000	3,794	7,000	7,510
9	Total Tax Expenses	4,000	3,000	3,794	7,000	7,510
10	Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0,000	0,000	0,000	0,000	0,000
11	Net Profit Loss for the period from continuing operations	15,137	9,061	12,697	24,198	24,898
12	Profit / (Loss) from discontinued operations before tax	0,000	0,000	0,000	0,000	0,000
13	Tax Expenses of discontinued operations	0,000	0,000	0,000	0,000	0,000
14	Net Profit / (Loss) from discontinued operations after tax	0,000	0,000	0,000	0,000	0,000

Jaydevin Chandra



15	Share of Profit / (Loss) of associates and joint ventures accounted for using equity method	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
16	Total Profit / (Loss) for the period	15,137	9,061	12,697	24,198	24,898	54,714		
17	Other Comprehensive Income net of Taxes	0.000	0.000	0.000	0.000	0.000	0.000		
18	Total Comprehensive Income for the Period	15,137	9,061	12,697	24,198	24,898	54,714		
19	Total profit or loss attributable to								
	Profit or loss, attributable to owners of parents	0.000	0.000	0.000	0.000	0.000	0.000		
	Total Profit or loss, attributable to non-controlling interests	0.000	0.000	0.000	0.000	0.000	0.000		
20	Total comprehensive income for the period attributable to								
	Comprehensive Income for the period attributable to the owners of parent non-controlling interests	0.000	0.000	0.000	0.000	0.000	0.000		
21	Details of Equity Share Capital								
	Paid-Up Equity Share Capital	299,030	299,030	299,030	299,030	299,030	299,030		
	Face Value of Equity Share Capital	10,000	10,000	10,000	10,000	10,000	10,000		
22	Details of Debt Securities								
	Paid-Up Debt Capital	0.000	0.000	0.000	0.000	0.000	0.000		
	Face Value of Debt Securities	0.000	0.000	0.000	0.000	0.000	0.000		
23	Reserves Excluding Revaluation Reserves	0.000	0.000	0.000	0.000	0.000	0.000		
24	Debt Redemption Reserve	0.000	0.000	0.000	0.000	0.000	0.000		
25	Earnings Per Share								
	Earnings Per Share for continuing operations								
	Basic Earnings / (Loss) per share from continuing operations	0.506	0.303	0.425	0.809	0.833	1.850		
	Diluted Earnings / (Loss) per share from continuing operations	0.506	0.303	0.425	0.809	0.833	1.850		
	Earnings Per Share for discontinued operations								
	Basic Earnings / (Loss) per share from discontinued operations	0.000	0.000	0.000	0.000	0.000	0.000		
	Diluted Earnings / (Loss) per share from discontinued operations	0.000	0.000	0.000	0.000	0.000	0.000		
	Earnings per Equity Share								
	Basic Earnings / (Loss) per share from continuing and discontinued operations	0.506	0.303	0.425	0.809	0.833	1.830		
	Diluted Earnings / (Loss) per share from continuing and discontinued operations	0.506	0.303	0.425	0.809	0.833	1.830		
26	Debt Equity Ratio	--	--	--	--	--	--		
27	Debt Service Coverage Ratio	--	--	--	--	--	--		
28	Interest Service Coverage Ratio	--	--	--	--	--	--		

Josephine M. ...



NOTES

1. The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on November 09, 2020.
2. The Limited Review of the results has been completed by the Statutory Auditors of the Company.
3. As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment viz. "Pharmaceutical Business".
4. The financial results for the quarter and half year ended 30th September, 2020 are also Ind AS compliant. The management has exercised necessary due diligence to ensure that the financial results give a true and fair view.
5. Previous quarter's amounts have been re-grouped/re-classified, wherever considered necessary to make them comparable with those of the current quarter.
6. Results are available at Company's website www.ishitadrugs.com and also at www.bseindia.com.

For, ISHITA DRUGS AND INDUSTRIES LIMITED



Jagdish Agrawal

JAGDISH AGRAWAL

MANAGING DIRECTOR

DIN: 01031687

Place	Ahmedabad	
Date	9-Nov-20	

ISHITA DRUGS AND INDUSTRIES LIMITED

CIN: L24231GJ1992PLC017054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand

Ahmedabad – 382170

Website: www.ishitadrugs.com

Contact: +91 7226995613

Statement of Assets and Liabilities

Amount in ₹

Particulars	Half Year Ended	Previous Year Ended
	6 Months Ended	12 Months Ended
	Unaudited	Audited
	30-Sep-20	31-Mar-20
ASSETS		
1 Non-current assets		
Property, plant and equipment	10482616	11369951
Capital work-in-progress		
Investment property		
Goodwill		
Other intangible assets		
Intangible assets under development		
Biological assets other than bearer plants		
Investments accounted for using equity method		
Non-current financial assets	10482616	11369951
Non-current investments	2068098	2068098
Trade receivables, non-current		
Loans, non-current		
Other non-current financial assets	506200	506200
Total Non-current financial assets	2574298	2574298
Deferred tax assets (net)		
Other non-current assets		
Total Non-current Assets	13056914	13944249
2 Current assets		
Inventories	8811428	5809314
Current financial assets		
Current investments	28601954	50866475
Trade receivables, current	24614420	13109812
Cash and cash equivalents	4354121	4017892
Bank balance other than cash and cash equivalent	5978175	5978175
Loans, current	0	0
Other current financial assets	276271	284000
Total current financial assets	63824940	74256353
Current tax assets (net)		
Other current assets		
Total Current Assets		
3 Non-current assets classified as held for sale		
4 Regulatory deferral account debit balances and related deferred tax Assets		
TOTAL ASSETS	85693282	94009916

Jeydevi Agrawal



EQUITIES AND LIABILITIES			
1	Equity		
	Equity attributable to owners of Parent		
	Equity share capital	29903000	29903000
	Other equity	42127380	39707583
	Total Equity attributable to owners of Parent	72030380	69610583
	Non controlling interest		
	Total Equity	72030380	69610583
2	Liabilities		
	Non-current liabilities		
	Non-current financial liabilities		
	Borrowing, non-current	214522	419487
	Trade payables, non-current		
	Other non-current financial liabilities		
	Total Non-current financial liabilities	214522	419487
	Provisions, non-current		
	Deferred tax liabilities (net)	469729	469729
	Deferred government grants, Non-current Other non-current liabilities		
	Total Non-current liabilities	469729	469729
	Current liabilities		
	Current financial liabilities		
	Borrowing, current	1393245	1655517
	Trade payables, current	7328238	18936050
	Other current financial liabilities	755558	993862
	Total current financial liabilities	9477041	21585429
	Other current liabilities		
	Provisions, current	4092997	1669022
	Current tax liabilities (Net)	-591387	255666
	Deferred government grants, Current		
	Total current liabilities	3501610	1924688
3	Liabilities directly associated with assets in disposal group classified as held for sale		
4	Regulatory deferral account credit balances and related deferred tax liability		
	Total Liabilities		
	Total Equity and Liabilities	85693282	94009916

For, ISHITA DRUGS AND INDUSTRIES LIMITED



Jagdish Agrawal

JAGDISH AGRAWAL

MANAGING DIRECTOR

Place Ahmedabad

Date 09-Nov-20

DIN: 01031687

ISHITA DRUGS AND INDUSTRIES LIMITED

CIN: L24231GJ1992PLC017054

**Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand
Ahmedabad – 382170**

Website: www.ishitadrugs.com

Contact: +91 7226995613

UNAUDITED CASH FLOW STATEMENT

Sr. No.	Perticulers	Unaudited Halfyear Ended 30.09.2020 Rs. In Lakhs	Audited Year Ended 31.03.2020 Rs. In Lakhs
(A)	Cash flow from operating activities :		
	Profit before tax	31.20	71.34
	Add : Depreciation	8.87	17.75
	Interest & Other financial charges	1.19	3.47
	Loss on sale of fixed assets	0.00	0.00
	Less : Interest received	2.28	4.56
	Dividend received	0.01	0.01
	Income from Investments	3.08	11.67
	Operating profit before change in working capital	35.89	76.33
	Add : Trade Debtors	(115.05)	(13.06)
	Decrease/(Increase) in Inventory	(30.02)	15.78
	Decrease/(Increase) in Loans and advances	0.08	(1.05)
	Less : Provision for Taxation	7.00	17.50
	Decrease/(Increase) Shore Term Provision	(24.24)	0.46
	Decrease/(Increase) Trade Creditors, Current liabilities & Provisions	124.83	(44.72)
	Net cash generated from operating activities (A)	(216.70)	104.75
(B)	Cash inflow from investing activities :		
	Add : Investment sold / (purchased)	222.65	(125.55)
	Dividend received	0.01	0.01
	Income from Investments	3.08	11.67
	Less : Investment in fixed assets	(0.00)	1.46
	Net cash generated from investing activities (B)	225.74	-115.33
(C)	Cash flow from financial activities :		
	Add : Interest received	2.28	4.56
	Borrowings	(6.77)	8.34
	Less : Interest & Other financial charges	1.19	3.47
	Net cash generated from financial activities (C)	(5.68)	9.42
	Net Increase/(decrease) in Cash & Cash Equivalents (A+B+C)	3.36	(1.15)
	Opening balance of Cash and cash equivalents	99.96	101.11
	Closing balance of Cash and cash equivalents	103.32	99.96
	Net Increase/(decrease) in Cash & Cash Equivalents	3.36	(1.15)

Note : Figures in bracket indicate negative value
Correctly extracted from Audited accounts of the Company

For, ISHITA DRUGS AND INDUSTRIES LIMITED

Jagdish Agrawal



JAGDISH AGRAWAL
MANAGING DIRECTOR

Place **Ahmedabad**
Date **09-Nov-20**

DIN: 01031687